Measurement of platelet interactions with subendothelial substrata: Relevance to transfusion medicine

Transfusion Medicine Reviews

Volumn 15, Issue 2, 2001, Pages 144-156

  Escolar, Ginés ^a   Galán, Ana María ^a   Mazzara, Roberto ^a   Castillo, Ricardo ^a   Ordinas, Antonio ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELL INTERACTION; CRYOPRESERVATION; HUMAN; HUMAN CELL; MEASUREMENT; MORPHOMETRICS; QUALITY CONTROL; REVIEW; STORAGE; SUBENDOTHELIUM; TECHNIQUE; THROMBOCYTE; TRANSFUSION;

EID: 0035051103     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1053/tm.rv.2001.22617     Document Type: Review

References (98)

1. Human platelet adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to the subendothelium
2. Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: A defect in platelet spreading
3. Glycoprotein VI is a major collagen receptor for platelet activation: It recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not
4. The role of platelet membrane glycoproteins Ib and IIb- IIIa in platelet adherence to human artery subendothelium
5. Platelet procoagulant activity: Phyisiological significance and mechanims of exposure
6. Further studies on the presence of functional tissue factor activity on the subendothelium of normal human and rabbit arteries
7. Activated factor VII activates factors IX and X on the surface of activated platelets: Thoughts on the mechanism of action of high-dose activated factor VII
8. Platelet Transfusion therapy: Platelet concentrate preparation and storage
9. Concepts about current conditions for the preparation and storage of platelets
10. Procoagulant effect of incompatible platelet transfusions in alloimmunized refractory patients
11. In vitro assessment of the quality of stored platelet concentrates
12. The thrombocytopenic rabbit bleeding time model to evaluate the in vivo hemostatic efficacy of platelets and platelet substitutes
13. The role of blood flow in plateletadhesion, fibrin deposition and formation of mural thrombi
14. Adhesion and aggregation: Morphological demonstration and quantitation in vivo and in vitro
15. Platelet adhesion and platelet thrombus formation on subendothelium of human arteries and veins exposed to flowing blood in vitro. A comparison with rabbit aorta
16. Automated microdensitometry and protein assays as a measure for platelet adhesion and aggregation on collagen-coated slides under controlled flow conditions
17. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components
18. Factor VIII-von Willebrand factor requires calcium for facilitation of platelet adherence
19. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. II. Relationships among platelet adhesion, thrombus dimensions, and fibrin formation
20. Activation of endothelial cells induces platelet thrombus formation on their matrix: Studies of new in vitro thrombosis model with low molecular weight heparin as anticoagulant
21. Platelet concentrates promote procoagulant activity: Evidence from experimental studies using a perfusion technique
22. Role of von Willebrand factor in platelet adhesion to the subendothelium
23. Regulation of platelet-fibrin thrombi on subendothelium
24. Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium: Studies utilizing patients with quantitative and qualitative platelet defects
25. Development of a computer program to analyze the parameters of platelet-vessel wall interaction
26. Platelet adhesion
27. The role of the Baumgartner technique in transfusion medicine: Research and clinical applications
28. Growth and stability of thrombi in flowing citrated blood: Assessment of platelet-surface interactions with computer-assisted morphometry
29. Digital image analysis of platelet-extracellular matrix interactions: Studies in von willebrand disease patients and aspirin-treated donors
30. Performance characteristics and clinical evaluation of an in vitro bleeding time device - Thrombostat 4000
31. Characterization of an in vivo platelet function analyzer, PFA-100™
32. Does the platelet-activated clotting test (HemoStatus®) predict blood loss and platelet dysfunction associated with cardiopulmonary bypass?
33. Xylum CSA: Automated system for assessing hemostasis in simulated vascular flow
34. Functional capacity of transfused platelets estimated by the Thrombostat-4000/2
35. Evaluation of the hemostatic function of stored platelet concentrates using the platelet function analyzer (PFA-100®)
36. Description of an in vitro platelet function analyzer-PFA-100™)
37. Effects of storage on platelet reactivity to arterial subendothelium during blood flow
38. Interaction of long-term stored platelets with vascular subendothelium
39. Evaluation of the transfusion effectiveness of various platelet concentrates by means of an invitro perfusion technique
40. Platelet activation may explain the storage lesion in platelet concentrates
41. Progressive platelet activation with storage - Evidence for shortened survival of activated platelets after transfusion
42. Quality control of platelet concentrates by the Thrombostat 4000
43. Prediction of the transfusion effect of platelet concentrates as measured by a model of primary hemostasis ex vivo
44. Pooled platelet concentrates prepared by the platelet-rich-plasma method and filtered with three different filters and stored for 8 days
45. In vitro evaluation of platelet concentrates, prepared from pooled huffy coats, stored for 8 days after filtration
46. The platelet adhesion capacity to subendothelial matrix and collagen in a flow model during storage of platelet concentrates for 7 days
47. Platelet concentrates prepared and stored under currently optimal conditions: Minor impact on platelet adhesive and cohesive functions after storage
48. Post-transfusion recovery of function of five-day stored platelet concentrates
49. Effects of the addition of second-messenger effects to platelet concentrates separated from whole-blood donations and stored at 4°C or -80°C
50. Effect of pre-incubation at 37 degrees C of platelet concentrates on the post-transfusion platelet adhesion capacity to collagen and fibrinogen
51. Platelet adhesion and thrombus formation on subendothelium in platelets deficient in glycoproteins IIb-IIIa, Ib, and storage granules
52. Transfusion of platelets and plasma products
53. Adenosine diphosphate in red cells as a factor in he adhesiveness of human blood platelets
54. Binding and inactivation of prostacyclin (PGI2) by human erythrocytes
55. Red blood cells: Their dual role in thrombus formation
56. Platelet interaction with subendothelium in a perfusion system: Physical role of red blood cell
57. Uraemic bleeding: Role of anemia and beneficial effect of red cell transfusion
58. Defective platelet adhesion on vessel subendothelium in uremic patients
59. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoeitin
60. Experimental basis for the use of red cell transfusion in the management of anemic-thrombocytopenic patients
61. The hemostatic effect of packed red cell transfusion in patients with anemia
62. Decreased adhesion of platelets to subendothelium in von Willebrand's disease
63. Association between bleeding time and platelet adherence to artery subendothelium
64. Adhesion of platelets to human artery subendothelium: Effect of factor VIII-von Willebrand factor of various multimeric composition
65. Treatment of von Willebrand disease
66. An intermediate-purity factor VIII concentrate supports platelet adhesion under flow conditions
67. Von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease
68. Binding of factor VIII-von Willebrand factor to human arterial subendothelium precedes increased platelet adhesion and enhances platelet spreading
69. Von Willebrand factor contained in a high purity FVIII concentrate (Fanhdi®) binds to platelet glycoproteins and supports platelet adhesion to subendothelium under flow conditions
70. Correction of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor
71. Studies on the prolonged bleeding time in von Willebrand's disease
72. DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitates. Evidence for a mechanism of action independent of released von willebrand factor
73. Platelet von Willebrand factor: An important determinant of the bleeding time in type I von Willebrand's disease
74. Transplantation of normal bone marrow into a pig with severe von Willebrand's disease
75. Platelet von Willebrand factor: Evidence for its involvement in platelet adhesion to collagen
76. Role for platelet von Willebrand factor in supporting platelet-vessel wall interactions in von Willebrand disease
77. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients
78. Hemostasis in patients with severe von Willebrand disease improves after normal platelet transfusion and normalizes with further correction of the plasma defect
79. Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases
80. Evaluation of the PFA-100® system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease
81. Therapeutic monitoring of von Willebrand disease: Interest and limits of a platelet function analyser at high shear rates
82. The Platelet Function Analyzer (PFA-100) may not be suitable for monitoring the therapeutic efficiency of von Willebrand concentrate in type III von Willebrand disease
83. Platelet membrane microparticles in blood bank fresh frozen plasma and cryoprecipitate
84. Platelet procoagulant activity and microvescile formation - Its putative role in hemostasis and thrombosis
85. Platelet membrane vesicles reduced microvascular bleeding times in thrombocytopenic rabbits
86. Platelet microvesicles adhere to subendothelium and promote adhesion of platelets
87. In vitro evaluation of the hemostatic effectiveness of non viable platelet preparations: Studies with frozen-thawed, sonicated or lyophilized platelets
88. The role of platelet microparticles in hemostasis
89. Infusible platelet membrane microvesicles: A potential transfusion substitute for platelets
90. Infusible platelet membranes (IPM) improve hemostasis in thrombocytopenic blood: Experimental studies under flow conditions
91. Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: Potential for long-term storage of dried platelets for transfusion
92. Activation and adherence of lyophilized human platelets on canine vessel strips in the Baumgartner perfusion chamber
93. Preparations of synthetic phospholipids promote procoagulant activity on damaged vessels: Studies under flow conditions
94. Assessment of potential thrombogenicity of coagulation factor IX concentrates in an in vitro model of human thrombogenesis
95. Fibrinogen-coated albuminin microcapsules reduce bleeding in severely thrombocytopenic rabbits
96. New developments in "artificial" blood products
97. Alternatives to standard blood transfusion: Availability and promise